BRACE CORONA: Continuing vs. suspending ACE inhibitors and ARBs in COVID-19
Reported from the European Society of Cardiology ESC Congress 2020
Reported from ESC Congress 2020 - Principal Investigator Renato Lopes (Durham, USA) discusses with Luis Ortega-Paz the results of the BRACE CORONA trial revealing that temporarily suspending use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) did not show clinical benefit in patients hospitalized with mild to severe COVID-19.
Dr. Lopes answers the following questions:
- Could you introduce the background, methodology, results and conclusion of the trial?
- How can you apply the results of the BRACE CORONA trial to patients who are asymptomatic, with moderate symptoms or with very severe symptoms?
- Could you tell us more about the secondary endpoints?
- Could you talk about the other trials you and your team are currently working on?
No comments yet!